Rifaximin Suppliers & Bulk Manufacturers

Available Forms: Tablet / Oral Suspension

Available Strengths: 100 mg/5 mL, 200 mg, 550 mg

Reference Brands: Xifaxan (USA), Targaxan (EU), Normix (LATAM)

Category: Antibiotics

Rifaximin is available in Tablet / Oral Suspension and strengths such as 100 mg/5 mL, 200 mg, 550 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Rifaximin is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Rifaximin can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Rifaximin is a minimally absorbed, gut-selective antibiotic that has gained significant attention for its role in the management of various gastrointestinal disorders. Belonging to the rifamycin class of antibiotics, rifaximin acts locally within the gastrointestinal tract and has very limited systemic absorption. This unique pharmaceutical property allows it to target harmful intestinal bacteria while maintaining a favorable safety profile. Because of its localized activity, rifaximin is widely used in conditions where modulation of the gut microbiota plays an important therapeutic role.

Clinically, rifaximin is used for the treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli, prevention of recurrence of hepatic encephalopathy, and management of irritable bowel syndrome with diarrhea (IBS-D). Ongoing research and clinical experience have also explored its potential benefits in other gastrointestinal conditions such as small intestinal bacterial overgrowth (SIBO), inflammatory bowel disorders, and other microbiota-related diseases.

The interest in rifaximin continues to grow due to its broad spectrum of activity against gram-positive and gram-negative bacteria within the gut, low risk of systemic side effects, and minimal drug interactions. Scientific literature highlights that its effectiveness is closely linked to its pharmacological characteristics, including stability in the gastrointestinal environment and its ability to alter bacterial composition without significant absorption into the bloodstream. As research advances, rifaximin remains an important therapeutic option in modern gastroenterology.